NewAmsterdam Pharma Company N.V. (NAMS)

SEC filing

NewAmsterdam Pharma Company N.V.

NAMS · CIK 1936258

4 · Oct 2, 2026 · Director, Chief Scientific Officer Kastelein Johannes Jacob Pieter sold 50.25K shares at $25.03/share ($1.3M); exercised options for 100.49K shares

Director, Chief Scientific Officer Kastelein Johannes Jacob Pieter sold 50.25K shares at $25.03/share ($1.3M); exercised options for 100.49K shares

Filed: Oct 2, 2026
Period: Sep 30, 2026
Accession: 0001193125-26-412431
Filer: NewAmsterdam Pharma Co N.V.

View on SEC.gov All SEC filings

Filing document

xslF345X06/ownership.xml

xslF345X06/ownership.xmlSEC.gov

Other files

Graphics and non-inline formats (not embedded below).

4ownership.xml
Open SEC.gov